MIN-117

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
MIN-117
MIN-117.svg
Clinical data
Synonyms WF-516
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
Formula C25H25Cl2N3O
Molar mass 502.392 g/mol
3D model (JSmol)

MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).[2][3][4] It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,[4][5][6] and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors.[4][6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.[3]

See also[edit]

References[edit]

  1. ^ Kato, Tadafumi; Saijo, Takeaki; Maeda, Jun; Okauchi, Takashi; Maeda, Jun-ichi; Morio, Yasunori; Kuwahara, Yasuhiro; Suzuki, Masayuki; Goto, Nobuharu; Fukumura, Toshimitsu; Suhara, Tetsuya; Higuchi, Makoto (2012). "Presynaptic Selectivity of a Ligand for Serotonin 1A Receptors Revealed by In Vivo PET Assays of Rat Brain". PLoS ONE. 7 (8): e42589. doi:10.1371/journal.pone.0042589. ISSN 1932-6203. PMC 3413639Freely accessible. PMID 22880045. 
  2. ^ "Minerva Neuroscience". Retrieved 2015-05-19. 
  3. ^ a b Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates". GlobalNewswire. Retrieved 2015-05-19. 
  4. ^ a b c Minerva Neurosciences. "Investor Presentation March 2015" (PDF). Archived from the original (PDF) on 2015-05-20. Retrieved 2015-05-19. 
  5. ^ "Company Profile for Minerva Neurosciences Inc". Reuters. Retrieved 2015-05-19. 
  6. ^ a b Don Dion (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved 2015-05-19. 

External links[edit]